4BIO CAPITAL is a trade name of 4BIO Ventures Management Ltd, which is authorised and regulated by the Financial Conduct Authority, register number 775193
© 2015-2019 by 4BIO Ventures Management Ltd

RNA-BASED THERAPY

  • RNA drugs potentially allow precise silencing or activation of genes
     

  • Advanced antisense RNA drugs enable precise control of gene expression, addressing diseases such as Huntington’s, DMD and SMA
     

  • Very rapid bioinformatics-based drug design cycles

THERAPEUTIC AREAS

  • Virology

  • Gain-of-function disorders

  • Liver disorders

  • Autoimmune disease